Physician profile
Anthony Martell
NPI 1982686275
$2,035.05
in general payments reported to CMS, 2019-2025
24 companies · $323 in 2025
The $323 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $57.18 · 2021: $400 · 2022: $372 · 2023: $313 · 2024: $295 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $377.87 | 2019-2025 | |
| Corium, LLC | $195.31 | 2021-2024 | Azstarys |
| Sanofi Pasteur INC. | $168.02 | 2019-2024 | |
| Glaxosmithkline, LLC. | $166.66 | 2019-2025 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $146.44 | 2020-2021 | |
| Alk-Abello, INC | $143.91 | 2023-2025 | Grastek, Odactra, Ragwitek |
| Cranial Technologies, INC | $133.76 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $101.28 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $98.66 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Seqirus USA INC | $84.66 | 2022-2025 | Flucelvax |
| Hologic Sales and Service, LLC | $50.26 | 2025 | Aptima, Thinprep 2000 Processor |
| Phadia US INC. | $46.53 | 2019-2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $46.38 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.24 | 2023 | Flumist Quadrivalent |
| Tris Pharma INC | $43.17 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $29.52 | 2022-2023 | |
| Kaleo, INC. | $27.21 | 2021-2022 | |
| Sobi, INC | $24.74 | 2023 | |
| Philips North America LLC | $19.57 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $19.37 | 2021 | |
| Genentech USA, INC. | $18.37 | 2019 | |
| Shire North American Group INC | $18.18 | 2019 | |
| Biomarin Pharmaceutical INC. | $17.95 | 2022 | |
| Vertical Pharmaceuticals, LLC | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Martell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.